Abstract
Objective The loss of noradrenergic neurons in the locus coeruleus contributes to neuropsychiatric symptoms in both Parkinson’s disease (PD) and progressive supranuclear palsy (PSP). This study aimed to characterise the spatial patterns of locus coeruleus pathological change in PD and PSP, and its relationship to cognitive and psychiatric symptoms.
Methods Twenty-five patients meeting clinical criteria for idiopathic PD, fourteen probable PSP-Richardson’s syndrome and twenty-four age-matched healthy controls (HC) were recruited. All participants underwent clinical assessments for cognition and apathy, and high-resolution (0.08 mm3) 7T-magnetisation-transfer imaging to measure LC integrity in vivo. To establish spatial patterns of locus coeruleus change, we obtained sub-region summaries of mean contrast ratios and significant locus coeruleus clusters using voxelwise analyses (family-wise-corrected p<0.05); we further correlated the locus coeruleus contrast with measures of apathy and cognition.
Results Reduced contrast was observed in the caudal locus coeruleus for both PD and PSP relative to controls, with significant regional and voxelwise differences (HC>PD, right caudal locus coeruleus, 37 voxels; HC>PSP, bilateral caudal locus coeruleus, 206 voxels). PSP and PD patients showed similar levels of locus coeruleus degeneration relative to controls, but this was spatially more extensive in PSP. Across both groups, variability of locus coeruleus integrity was associated with cognitive performance (MoCA: 200 voxels; ACE-R: 70 voxels) and apathy (Apathy Scale: 99 voxels).
Conclusions The relationship between locus coeruleus structure and non-motor symptoms highlights a role for noradrenergic dysfunction across both PD and PSP, confirming the potential for noradrenergic therapeutic strategies to address transdiagnostic cognitive and behavioural features in neurodegenerative disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Parkinson's UK (K-1702); the Cambridge Centre for Parkinson-Plus; the China Scholarship Council; a Neil Hamilton Fairley Fellowship from the Australian National Health and Medical Research Council (GNT1091310); a Cambridge Trust Vice-Chancellor's Award and Fitzwilliam College Scholarship; the Association of British Neurologists-Patrick Berthoud Charitable Trust (RG99368); the Medical Research Council (SUAG/051 G101400; MR/P01271X/1); James S. McDonnell Foundation 21st Century Science Initiative Scholar Award in Understanding Human Cognition; the Wellcome Trust (103838); a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1); the NIHR Cambridge Clinical Research Facility and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the local Cambridge Research Ethics Committees (REC reference: 10/H0308/34) and all participants provided written informed consent according to the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The MT and MP2RAGE data used in this study are available for non-commercial academic purposes upon request.